Thoratec Seeks Therapeutic VAD, Others Aim For Alternative-To-Transplant
This article was originally published in The Gray Sheet
Executive Summary
Thoratec plans to file a PMA supplement for a therapeutic recovery indication for the Thoratec ventricular assist device (VAD) by year-end.
You may also be interested in...
Abiomed Pumps Cash Into Eleventh-Hour Bid For Thermo CardioSystems
Abiomed may be able to leverage its strength in the capital markets - specifically, an enhanced cash position resulting from a $95 mil. secondary offering last March - to undercut a previously announced all-stock bid by Thoratec for ventricular assist device developer Thermo CardioSystems.
Abiomed Pumps Cash Into Eleventh-Hour Bid For Thermo CardioSystems
Abiomed may be able to leverage its strength in the capital markets - specifically, an enhanced cash position resulting from a $95 mil. secondary offering last March - to undercut a previously announced all-stock bid by Thoratec for ventricular assist device developer Thermo CardioSystems.
WorldHeart Gaining Access To U.S. VAD Market Via Edwards' Novacor
WorldHeart will gain immediate access to the U.S. left ventricular assist device market through Edwards Lifesciences' Novacor ventricular assist system under a definitive licensing agreement announced May 25.